INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.'s Board Of Directors For Breach of Fiduciary Duties (PFE)

newsfile02:06 ET

CICC: Maintains AKESO rating of "outperforming the industry" with a Target Price of 90 Hong Kong dollars.

CICC released a Research Report stating that it maintains AKESO (09926) with an "outperforming the Industry" rating and a Target Price of 90 Hong Kong dollars, while keeping the profit forecasts for 2025 and 2026 unchanged. On February 24, the company's partner Summit announced that it had reached a clinical trial cooperation agreement with Pfizer to jointly explore the combined treatment potential of AK112 and several ADC drugs from Pfizer in solid tumors. The main points from CICC are as follows: The international value of AK112 has been recognized, exploring the combined potential with ADC. According to the cooperation agreement, Pfizer will be fully responsible for the clinical trials involved in this cooperation, while Summit will provide AK1.

Sina Hong Kong Stocks21:50 ET

Pfizer Options Spot-On: On February 25th, 199.51K Contracts Were Traded, With 2.93 Million Open Interest

Moomoo News16:30 ET

Wall Street Today: All Fun and Games Until Consumers Get Uneasy

Kevin Travers16:13 ET

Express News | Ukraine Agrees to U.S. Mineral Deal: Financial Times

Moomoo 24/714:56 ET

Live Stock News: Tesla, Bitcoin, Major Mag Seven Tech Pullback

Kevin Travers11:20 ET